Ritonavir

The Ritonavir molecule - rotatable in 3 dimensions

Ritonavir, also known as Norvir, was developed as an antiretroviral medication, specifically an inhibitor of HIV protease.

It is used along with other medications as highly active antiretroviral therapy (HAART) to treat HIV/AIDS .

At a low dose it is used with other protease inhibitors such as Paxlovid, targetted at coronaviral protease.

Additionally it has been found that ritonavir reduces the activity of cytochrome P450 enzymes in the liver that metabolise certain drugs, allowing these medications to remain at an active concentration for longer

Molecular dynamics analysis of a number of compounds predicted ritonavir has the best potential for blocking the binding of the SARS-CoV-2 spike (S) protein to the human angiotensin-converting enzyme-2 (hACE2) receptor, which is critical for the virus entry into human cells.

Label/ Unlabel atoms

Supporting units on this site


HIV a section within the Cell recognition topic

Paxlovid

Efavirenz Non-nucleoside reverse transcriptase inhibitor (NNRTI)

Web references

Ritonavir From Wikipedia, the free encyclopedia

Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding

Covid: Pfizer says antiviral pill 89% effective in high-risk cases By Jim Reed and Philippa Roxby BBC News

Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study